EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Long-Term Cognitive Impairment After CAR-T Therapy Versus Autologous Stem Cell Transplantation: A Propensity Score-Matched Cohort Study

Anna Blyzniuk iD, Po-Huang Chen iD, Wei-Cheng Chang iD, Hsin-Yu Chen iD, Li-Ting Kao, Tina Yi-Jin Hsieh, Ming-Shen Dai iD, Hong-Jie Jhou, Cho-Hao Lee iD

Diagnostics · 16.06.2026 · 16 (12) · 1862

DOI: 10.3390/diagnostics16121862 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diagnostics, online erschienen am 16.06.2026. Verfasst von Anna Blyzniuk und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, O.O. Bogomolets National Medical University, 01601 Kyiv, Ukraine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed outcomes in relapsed or refractory hematologic malignancies, but long-term cognitive outcomes remain poorly understood. We compared the incidence and time course of cognitive impairment and associated neurological complications after CAR-T therapy compared with autologous stem cell transplantation (ASCT).

Methods

This retrospective, propensity-matched cohort study utilized the TriNetX US Collaborative Network (January 2014–April 2025). To ensure concurrent comparisons, ASCT recipients were restricted to an index date beginning in August 2017 or later. CAR-T recipients were matched 1:1 to ASCT recipients for demographics, disease, comorbidities, prior and concomitant treatments, and laboratory parameters. The primary endpoint was time to cognitive impairment, as defined by ICD-10 codes.

Results

After comparing 3067 CAR-T patients (median follow-up 634 days) with 3067 ASCT patients (median follow-up 713 days), CAR-T recipients had a higher risk of cognitive impairment (HR 1.58; 95% CI 1.39–1.80; p < 0.001). Because the risks were not proportional (Schaenfeld p < 0.001), the difference was also expressed as restricted median survival time (RMST): CAR-T recipients spent approximately 25 and 53 days fewer days without cognitive impairment at 1 and 2 years, respectively (both p < 0.001). The risk was greatest at 30 days (HR 4.22; 95% CI 3.23–5.53), but remained elevated in control analyses at 30 and 90 days that excluded the acute ICANS window (HR 1.30 and 1.25, respectively; both p < 0.05). Neurological dysfunction, particularly encephalopathy (HR 2.04; 95% CI 1.73–2.40), was more common after CAR-T. Conversely, CAR-T was associated with a reduced risk of secondary acute myeloid leukemia (HR 0.46; 95% CI 0.38–0.55; p < 0.001).

Conclusions

CAR-T therapy is associated with a higher risk of cognitive impairment that persists beyond the acute phase. As these are observational, code-based data, they should be interpreted as associations rather than evidence of a specific mechanism, and they highlight the need for informed consent discussions, long-term neurocognitive monitoring, and the development of neuroprotective strategies.

Schlagwörter

Stichwörter der Autor:innen

CAR-T cell therapyTriNetXautologous stem cell transplantationcognitive impairmenthematological malignanciesimmune effector cell-associated neurotoxicity syndrome (ICANS)neurotoxicitypropensity score matchingreal-world evidence

Autor:innen und Institutionen

  • School of Medicine, O.O. Bogomolets National Medical University, 01601 Kyiv, Ukraine.
  • Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan.
  • Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan.
  • Department of Ophthalmology, Universe Eye Center, Hsinchu 30055, Taiwan.
  • Department of Family Medicine, Chi Mei Medical Center, Tainan 71004, Taiwan.
  • Graduate Institute of Life Sciences, National Defense Medical University, Taipei 11490, Taiwan.

ORCID-Profile: Anna Blyzniuk, Po-Huang Chen, Wei-Cheng Chang, Hsin-Yu Chen, Ming-Shen Dai, Cho-Hao Lee

Zitieren

APA

Blyzniuk, A., Chen, P. H., Chang, W. C., Chen, H. Y., Kao, L. T., Hsieh, T. Y., Dai, M. S., Jhou, H. J., & Lee, C. H. (2026). Long-Term Cognitive Impairment After CAR-T Therapy Versus Autologous Stem Cell Transplantation: A Propensity Score-Matched Cohort Study. Diagnostics, 16(12), 1862. https://doi.org/10.3390/diagnostics16121862

Vancouver

Blyzniuk A, Chen PH, Chang WC, Chen HY, Kao LT, Hsieh TY, et al. Long-Term Cognitive Impairment After CAR-T Therapy Versus Autologous Stem Cell Transplantation: A Propensity Score-Matched Cohort Study. Diagnostics. 2026;16(12):1862. doi:10.3390/diagnostics16121862

BibTeX
@article{Blyzniuk2026,
  author = {Blyzniuk, Anna and Chen, Po-Huang and Chang, Wei-Cheng and Chen, Hsin-Yu and Kao, Li-Ting and Hsieh, Tina Yi-Jin and Dai, Ming-Shen and Jhou, Hong-Jie and Lee, Cho-Hao},
  title = {Long-Term Cognitive Impairment After CAR-T Therapy Versus Autologous Stem Cell Transplantation: A Propensity Score-Matched Cohort Study},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {12},
  pages = {1862},
  doi = {10.3390/diagnostics16121862}
}
Kostenlos starten →